Literature DB >> 18974173

Memory and mood during the night and in the morning after repeated evening doses of MDMA.

K P C Kuypers1, M Wingen, J G Ramaekers.   

Abstract

Previously it has been shown that MDMA causes memory impairment during daytime testing. However, MDMA is usually taken in the evening or during the night. In addition, it is known that sleep deprivation also causes memory impairment. The present study aimed to assess whether evening doses of MDMA added to, or interacted with the memory impairment due to sleep deprivation. Fourteen healthy subjects participated in a double-blind, placebo-controlled, two-way cross-over study. Treatments consisted of MDMA 75 and 50 mg divided over the evening or double placebo. Memory tests and subjective measures of mood were conducted at baseline and three times post dosing that is at 6.30 pm, 9.30 pm, 1.30 am and 7 am, respectively -1.5, 1.5, 5.5 and 11 h relative to drug intake (first dose). Memory performance detoriated progessively over time as a function of sleep loss, independent of treatment. MDMA added to this impairment as indicated by a significant main effect of MDMA on verbal and spatial memory performance. Mood ratings and response speed revealed an MDMA by Time interaction. After administration of MDMA response speed improved and feelings of vigor, friendliness, elation, anxiety, confusion, arousal and positive mood increased in magnitude during the night, while all these parameters returned to placebo-like levels on the final morning session. It is concluded that evening doses of MDMA selectively impair memory performance, and that this impairment is additional to the effect of sleep deprivation on memory performance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974173     DOI: 10.1177/02698811080220081401

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  6 in total

1.  MDMA (ecstasy) effects on actual driving performance before and after sleep deprivation, as function of dose and concentration in blood and oral fluid.

Authors:  Wendy M Bosker; Kim P C Kuypers; Silke Conen; Gerold F Kauert; Stefan W Toennes; Gisela Skopp; Johannes G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2011-09-28       Impact factor: 4.530

2.  Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans.

Authors:  Elizabeth B de Sousa Fernandes Perna; Eef L Theunissen; Patrick C Dolder; Natasha L Mason; Nadia R P W Hutten; Stefan W Toennes; Kim P C Kuypers; Johannes G Ramaekers
Journal:  Front Pharmacol       Date:  2018-07-06       Impact factor: 5.810

3.  Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss.

Authors:  Wendy M Bosker; Kim P C Kuypers; Silke Conen; Johannes G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2010-03       Impact factor: 4.530

4.  A Systematic Review of the MDMA Model to Address Social Impairment in Autism.

Authors:  Devahuti Chaliha; John C Mamo; Matthew Albrecht; Virginie Lam; Ryu Takechi; Mauro Vaccarezza
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 5.  3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Authors:  Jerrold S Meyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-21

6.  Does ±3,4-methylenedioxymethamphetamine (ecstasy) induce subjective feelings of social connection in humans? A multilevel meta-analysis.

Authors:  Annie Regan; Seth Margolis; Harriet de Wit; Sonja Lyubomirsky
Journal:  PLoS One       Date:  2021-10-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.